Merck's New HIV Pill: Hope for Global Prevention

Merck announced on Friday, July 25, 2026, that it will license seven generic drugmakers to produce a low-cost version of its new monthly HIV prevention pill, alimatravir. This decision aims to make stockpiles of the drug available in developing countries if clinical trial results are positive next year.

The announcement coincides with a major international AIDS conference in Rio de Janeiro. Alimatravir is a monthly pill for pre-exposure prophylaxis (PrEP) currently in late-stage trials involving young women in sub-Saharan Africa and transgender individuals and men who have sex with men across Latin America, Asia, Europe, and Africa.

Merck's agreement covers 129 low- and middle-income countries, with licenses granted to four Indian companies and three African drugmakers in Uganda, Kenya, and South Africa. This initiative supports regional manufacturing, a priority for the African Union.

Alimatravir's production is cost-effective, potentially allowing sales to national health systems for as little as $5 per person per year. This proactive licensing, ahead of final trial results, seeks to avoid past access issues with other PrEP products. Advocates are working with Merck to ensure broad access should the drug prove effective.

HIV researchers, including those supported by the Gates Foundation's $100 million investment, express significant optimism about alimatravir's potential. Studies show protection starting within an hour, with a week-long grace period for missed doses, making it a potentially transformative tool.

Unlike daily pills or injections, alimatravir's monthly dosage is easier to distribute, even outside traditional clinics. Merck is also negotiating supply deals for Latin America, including Brazil, aiming for rapid and affordable access, although challenges persist in the region due to pricing and access barriers with other long-acting prevention methods.